NASDAQ: SEPNSepterna Inc Stock
$36.03+0.08 (+0.22%)
Updated Jun 15, 2026
SEPN Price
$36.03
Fair Value Price
-$32.08
Market Cap
$1.62B
52 Week Low
$9.85
52 Week High
$37.00
P/E
-44.48x
P/B
4.29x
P/S
14.89x
PEG
N/A
Dividend Yield
N/A
Revenue
$72.26M
Earnings
-$36.04M
Gross Margin
100%
Operating Margin
-49.4%
Profit Margin
-49.9%
Debt to Equity
0.51
Operating Cash Flow
$108M
Beta
1.37
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SEPN Overview
Septerna, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the identification and advancement of orally administered, small molecule therapies that modulate G protein-coupled receptors (GPCRs). The company's pipeline is designed to address a spectrum of conditions within endocrinology, immunology and inflammation, and metabolic disorders. Among its key programs, Septerna is developing SEP-786, an oral small molecule serving as a PTH1R agonist for individuals suffering from hypoparathyroidism. Another candidate, SEP-631, is an oral small molecule MRGPRX2 NAM aimed at treating chronic spontaneous urticaria and other mast cell-related ailments. Furthermore, its TSHR Program involves an oral small molecule TSHR NAM for both Graves' disease and thyroid eye disease. The company is also progressing oral small molecule single- and multi-incretin receptor agonists to tackle metabolic issues such as obesity and type 2 diabetes. Founded in 2019, Septerna, Inc. is headquartered in South San Francisco, California. It was formerly known as GPCR NewCo, Inc. until its rebranding to Septerna Inc. in June 2021.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SEPN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SEPN
Ranked#37 of 462
Ranked#37 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.59 | A | |
| $53.00 | A | |
| $16.00 | A |
Be the first to know about important SEPN news, forecast changes, insider trades & much more!
SEPN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SEPN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SEPN ($36.03) is overvalued by 212.31% relative to our estimate of its Fair Value price of -$32.08 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SEPN ($36.03) is not significantly undervalued (212.31%) relative to our estimate of its Fair Value price of -$32.08 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SEPN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SEPN due diligence checks available for Premium users.
Valuation
SEPN fair value
Fair Value of SEPN stock based on Discounted Cash Flow (DCF)
Price
$36.03
Fair Value
-$32.08
Undervalued by
212.31%
SEPN ($36.03) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SEPN ($36.03) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SEPN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SEPN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-44.48x
Industry
16.41x
Market
14.3x
SEPN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.29x
Industry
4.89x
SEPN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SEPN's financial health
Profit margin
Revenue
$26.5M
Net Income
-$8.6M
Profit Margin
-32.6%
SEPN's Earnings (EBIT) of -$35.69M... subscribe to Premium to read more.
Interest Coverage Financials
SEPN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$569.7M
Liabilities
$191.2M
Debt to equity
0.51
SEPN's short-term assets ($368.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SEPN's short-term assets ($368.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SEPN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$25.6M
Investing
-$23.8M
Financing
$333.0k
SEPN's operating cash flow ($107.90M)... subscribe to Premium to read more.
Debt Coverage Financials
SEPN vs Biotech Stocks
Septerna Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.